Investment & transaction experience

Capital judgment
across the cycle.

Direct investing, structured credit, biotechnology, special situations, litigation finance, and operating finance—from origination and diligence through monitoring, restructuring, and exit.

Career scale

Experience measured in decisions, not labels.

$1B+Cumulative capital managed across public and private portfolios

$500M+Direct investments across equity, credit, and litigation finance

55Direct investments structured and executed

$250M+Healthcare-focused leveraged-loan portfolio

150+Leveraged-credit underwritings

250+Investment-committee presentations

The capital figures are cumulative across career mandates, not simultaneous assets under management. Direct investments are a subset of total capital managed; the figures are not additive.

Experience by platform

A consistent process across different markets.

Palladin / Imperium

Direct investing & special situations · 1998–2010

Led Palladin’s healthcare book, which reached approximately $300 million across PIPEs, convertible and merger arbitrage, and derivative strategies. Separately managed the $30 million Palladin Opportunity Fund, which began at approximately $9 million, and held investment responsibility at Imperium.
Structured and executed 55 direct investments totaling $225 million for Palladin Halifax. Equity-line trading and hedging activity created additional turnover, which is not counted as new direct investment capital.
Worked directly with issuers to design, negotiate, and execute securities combining conversion rights, warrants, contingent economics, and downside protections; adapted positions through hedging, trading, and restructuring.
Named examples include VaxGen, ChromaVision, Entelos, and a proposed Cerus senior-secured note and warrant financing.

Hildene

Structured & healthcare credit · 2011–2016

Developed credit-rating methods and surveillance processes supporting more than 500 regional-bank credits.
Managed approximately $250 million of healthcare-focused investments across hospitals, pharmaceuticals, diagnostics, nursing facilities, and specialty providers. Evaluated leveraged loans from the investor side, assessing borrower fundamentals, documentation, leverage, collateral, and recovery.
Produced more than 250 investment-committee presentations covering investment, valuation, sizing, risk, monitoring, and exit.

Long Focus Capital

Biotechnology investing · 2016–2019

Managed approximately $50 million in healthcare and biotechnology investments in partnership with the firm’s founder.
Led scientific, clinical, commercial, and financial diligence across biotechnology and pharmaceutical opportunities.
Co-managed a biotechnology portfolio that nearly tripled over a two-year period through research and portfolio construction.

Dislocation

Leveraged-credit portfolio management

Managed approximately $200–250 million in leveraged loans under a distinct investment mandate.
Applied fundamental credit underwriting, portfolio construction, surveillance, valuation, and recovery analysis to institutional loan exposure.

Golub Capital

Credit monitoring & valuation · 2019–2020

Senior member of the valuation and credit-monitoring team for technology, software, and healthcare credits.
Conducted fundamental credit analysis, portfolio surveillance, and valuation review across private borrowers.

ACI — Litigation Finance

Portfolio management & advisory · 2021–present

Managed and advised on litigation-finance exposures reaching approximately $200 million, including the development of a substantial specialty-finance platform.
Combined medical, epidemiological, and causation analysis with case-level underwriting, settlement modeling, portfolio valuation, acquisition strategy, capital formation, and credit protections.
Named strategies include Camp Lejeune and AFFF/PFAS; counterparties and current marks remain confidential.

Current Operating Finance

Fractional CFO & executive leadership · 2025–present

Financial leadership for an integrated marketing and technology platform serving legal, healthcare, and mass-tort industries.
Advises ownership on strategy, capital allocation, budgeting, forecasting, KPIs, financing alternatives, organization, and profitability.

Selected transactions and strategies

Representative evidence.

Strategy	Transaction / asset	Platform	Role
Biotechnology PIPE	VaxGen	Direct-investment platform	$15 million lead participation in a $20 million structured financing; active monitoring through changing clinical and corporate facts.
Medical-technology PIPE	ChromaVision	Direct-investment platform	$5 million lead position in a $12.5 million preferred-and-warrant financing; trading, hedging, and restructuring.
Healthcare technology credit	Entelos	Special-situations platform	$5 million senior-secured convertible debenture position; asset, covenant, and restructuring analysis.
Structured private credit	Cerus Corporation	Special-situations platform	Developed a proposed senior-secured note, warrant package, covenants, and follow-on option; detailed economics remain confidential.
Mass-tort case acquisition	Camp Lejeune	Advisory platform	Portfolio acquisition, financing, valuation, risk monitoring, and investor communication.
Environmental personal injury	AFFF / PFAS	Advisory platform	Inventory sourcing, exposure and disease underwriting, vendor assessment, and portfolio valuation.
Structured credit	Regional-bank TruPS / CDOs	Alternative asset manager	Underlying-bank analysis, cash-flow and recovery frameworks, ratings, and surveillance.
Healthcare leveraged loans	Anonymized portfolio	Alternative asset manager	Underwriting, monitoring, valuation, investment committee, sizing, and exit decisions.

Aggregate figures describe different and potentially overlapping scopes. Structured equity-line throughput is excluded from the recorded funded total. Certain borrower, client, counterparty, and transaction details are omitted for confidentiality.

Capital judgmentacross the cycle.